Eag1: an emerging oncological target.
Emerging evidence indicates that ion channels act in a variety of physiologic and pathologic processes beyond electronic signal transmission, including in cancer. We recently found that the potassium channel Eag1 can mediate cancer progression and that a monoclonal antibody, which inhibits Eag1 action, can effectively restrict cancer cell proliferation. We discuss how Eag1 targeting may be useful in diagnostic or therapeutic settings.
Pardo
Luis A
LA
Max-Planck Institute of Experimental Medicine, Göttingen, Germany. pardo@em.mpg.de
Stühmer
Walter
W
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human